Understand the source comparison
LL-37 Help Mold Illness Research: Mechanisms Comparison
The table below compares LL-37's primary mechanisms of action relevant to mold illness research, the supporting evidence for each mechanism, and the clinical or experimental relevance to biotoxin-exposed populations. Fungal membrane disruption 70% growth inhib
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares LL-37's primary mechanisms of action relevant to mold illness research, the supporting evidence for each mechanism, and the clinical or experimental relevance to biotoxin-exposed populations.
- Fungal membrane disruption
- 70% growth inhibition of Aspergillus fumigatus at 10 μg/mL (Journal of Immunology)
- Direct pathogen clearance in sinus/respiratory colonisation
- Allows dose-response testing of antifungal activity in vitro
- LL-37's membrane-disrupting activity is fungicidal, not fungistatic. Kills pathogens rather than suppressing growth
- Biofilm disruption
- 60% reduction in Candida biofilm density in controlled assays
- Prevents persistent colonisation that evades immune clearance
- Models chronic fungal presence in mucosal tissues
- Biofilm activity addresses a key failure point in chronic mold illness. Why pathogens persist despite immune activation
- Cytokine modulation (IL-6, TNF-alpha reduction)
- 35–50% reduction in pro-inflammatory cytokines in mycotoxin-exposed macrophages
- Reduces inflammatory cascade driving CIRS symptomatology
- Quantifies anti-inflammatory effects independent of pathogen killing
- LL-37 doesn't just kill fungi. It dampens the cytokine storm that persists even after pathogen clearance
- Epithelial barrier restoration
- Increased occludin/claudin-1 expression in Aspergillus-exposed bronchial cells
- Repairs 'leaky gut' and respiratory barrier dysfunction in biotoxin exposure
- Identifies tight junction repair as a therapeutic target
- Barrier dysfunction is a suspected mechanism for systemic mycotoxin translocation. LL-37 may reverse it
- Vitamin D-dependent upregulation
- VDR activation increases CAMP gene expression and LL-37 production
- Explains why vitamin D deficiency correlates with CIRS severity
- Links nutritional interventions to innate immune recovery
- Patients with VDR polymorphisms may not upregulate LL-37 adequately even with vitamin D supplementation
- TGF-beta1 suppression of LL-37
- Elevated TGF-beta1 in CIRS patients suppresses VDR and LL-37 expression
- Explains why biotoxin-exposed patients show low LL-37 despite infection
- Identifies TGF-beta1 as upstream target for restoring LL-37 activity
- Correcting TGF-beta1 dysregulation may be prerequisite for LL-37 restoration. Direct supplementation bypasses this